Right Ventricular Dysfunction and Remodeling in Chronic Obstructive Pulmonary Disease Without Pulmonary Hypertension
Overview
Authors
Affiliations
Objectives: The aim of the present study was to elucidate right ventricular (RV) function and structure in patients with chronic obstructive pulmonary disease (COPD) without pulmonary hypertension (PH).
Background: There is little knowledge of RV function and remodeling in COPD without PH.
Methods: Thirty-four controls and 98 patients with COPD were included. The study patients were divided into 2 groups by right heart catheterization: no PH (mean pulmonary artery pressure [mPAP] <25 mm Hg) and PH (mPAP ≥25 mm Hg). The echocardiographic tissue Doppler imaging variables of RV isovolumic acceleration, peak systolic strain, and RV myocardial performance index were measured at the basal free wall, and RV wall thickness and RV internal dimension were measured in the RV outflow tract.
Results: The increases in RV wall thickness and RV dimension were more evident when comparing controls with the no PH group (3.5 ± 0.5 mm to 5.5 ± 1.0 mm [p < 0.01] and 1.5 cm ± 0.2 to 2.0 ± 0.5 cm [p < 0.01]) than comparing the no PH group with the PH group (5.5 ± 1.0 mm to 6.6 ± 1.1 mm [p < 0.01] and 2.0 cm ± 0.5 to 2.1 ± 0.3 cm [p = NS]), respectively. Similarly, RV isovolumic acceleration, performance index, and strain deteriorated significantly when comparing controls with the no PH group and comparing the no PH group with the PH group (p < 0.01). Significant correlations were observed between mPAP and RV isovolumic acceleration, performance index, strain, and RV wall thickness (p < 0.01). RV impairment and increased RV wall thickness and RV dimensions were present even at slight elevations of mPAP (18 ± 3 mm Hg) in the no PH group.
Conclusions: The present study showed that impaired RV systolic function, hypertrophy, and dilation were present even at a slight increase of mPAP, which indicates an early impact on RV function and structure in patients with COPD. RV isovolumic acceleration, performance index, and strain could detect subclinical disease and separate controls from those with no PH.
Nguyen Ngoc Dang H, Viet Luong T, Thi Y Nguyen N, Khanh Tran H, Thi Nguyen Tran H, Minh Vu H BMJ Open Respir Res. 2025; 12(1).
PMID: 40050037 PMC: 11887318. DOI: 10.1136/bmjresp-2024-002706.
Sonaglioni A, Caminati A, Nicolosi G, Muti-Schunemann G, Lombardo M, Harari S J Clin Med. 2025; 14(3).
PMID: 39941384 PMC: 11818070. DOI: 10.3390/jcm14030714.
Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.
Nakamura K, Akagi S, Ejiri K, Taya S, Saito Y, Kuroda K Int J Mol Sci. 2025; 26(2).
PMID: 39859549 PMC: 11765551. DOI: 10.3390/ijms26020835.
Preiss H, Mayer L, Furian M, Schneider S, Muller J, Saxer S Open Heart. 2025; 12(1.
PMID: 39756820 PMC: 11752043. DOI: 10.1136/openhrt-2024-002837.
Pathophysiology of the right ventricle and its pulmonary vascular interaction.
Hemnes A, Celermajer D, DAlto M, Haddad F, Hassoun P, Prins K Eur Respir J. 2024; 64(4).
PMID: 39209482 PMC: 11525331. DOI: 10.1183/13993003.01321-2024.